title: Immunology of protection from Ebola virus infection.
abstract: A December 2014 meeting reviewed Ebola virus immunology relevant to vaccine development, including Ebola prevention, immunity, assay standardization, and regulatory considerations. Vaccinated humans appear to achieve immune responses comparable in magnitude with those associated with protection in nonhuman primates, suggesting that immunological data could be used to demonstrate vaccine efficacy.
authors.affiliation: Office of Vaccines Research and Review, U.S. Food and Drug Administration/Center for Biologics Evaluation and Research, Silver Spring, MD, USA. philip.krause@fda.hhs.gov.
authors.forename: Philip R
authors.initials: PR
authors.lastname: Krause
authors.affiliation: Division of Microbial and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Paula R
authors.initials: PR
authors.lastname: Bryant
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, GA, USA.
authors.forename: Thomas
authors.initials: T
authors.lastname: Clark
authors.affiliation: Division of Microbial and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Walla
authors.initials: W
authors.lastname: Dempsey
authors.affiliation: Office of Vaccines Research and Review, U.S. Food and Drug Administration/Center for Biologics Evaluation and Research, Silver Spring, MD, USA.
authors.forename: Erik
authors.initials: E
authors.lastname: Henchal
authors.affiliation: Walter Reed Army Institute of Research, Silver Spring, MD, USA.
authors.forename: Nelson L
authors.initials: NL
authors.lastname: Michael
authors.affiliation: Walter Reed Army Institute of Research, Silver Spring, MD, USA.
authors.forename: Jason A
authors.initials: JA
authors.lastname: Regules
authors.affiliation: Office of Vaccines Research and Review, U.S. Food and Drug Administration/Center for Biologics Evaluation and Research, Silver Spring, MD, USA.
authors.forename: Marion F
authors.initials: MF
authors.lastname: Gruber
mesh_terms: D000256:Adenoviridae / Q000276:immunology; D000354:Africa, Western; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D002487:Centers for Disease Control and Prevention, U.S.; D003226:Congresses as Topic; D046129:Ebola Vaccines / Q000276:immunology / Q000627:therapeutic use*; D029043:Ebolavirus / Q000276:immunology; D019142:Hemorrhagic Fever, Ebola / Q000276:immunology* / Q000517:prevention & control*; D006801:Humans; D056724:Immunity, Humoral; D054579:National Institute of Allergy and Infectious Diseases (U.S.); D016032:Randomized Controlled Trials as Topic; D014481:United States; D014486:United States Food and Drug Administration; D014611:Vaccination
chemical_list: D000914:Antibodies, Viral; D046129:Ebola Vaccines